October 12, 2025Open Access

The V617F mutation in JAK2 renders myeloid cells more sensitive to IL-6-mediated gp130 signaling

View Full Paper

Ask AI

Bookmark

Authors

HSHenning Schurse MTMarcelo Szymanski de Toledo AKAndrea Küster

Discussion

Member takes

Overview

Molecular dynamics simulations reveal V617F mutations enhance gp130 dimerization and IL-6 sensitivity in myeloid cells, indicating potential therapeutic targets.

Key Points

The V617F mutation in JAK2 significantly enhances sensitivity to IL-6 in myeloid cells, promoting chronic inflammation and disease progression.
Molecular dynamics simulations showed that JAK2VF forms more stable dimers than wild-type JAK2, leading to stronger STAT3 activation.
Increased gp130 receptor levels were observed in JAK2VF+ cells, enhancing their response to IL-6 stimulation compared to wild-type cells.
This mutation represents a critical target for therapies aimed at managing myeloproliferative neoplasms and associated inflammatory symptoms.

Cite This Study

Schurse et al. (2025) studied this question.

synapsesocial.com/papers/68ebffcfdef9fcb308ff230b https://doi.org/10.1101/2025.10.10.681590

View Full Paper

Ask AI

Bookmark

October 12, 2025Open Access

The V617F mutation in JAK2 renders myeloid cells more sensitive to IL-6-mediated gp130 signaling

View Full Paper

Ask AI

Bookmark

Authors

HSHenning Schurse MTMarcelo Szymanski de Toledo AKAndrea Küster

Discussion

Member takes

Overview

Molecular dynamics simulations reveal V617F mutations enhance gp130 dimerization and IL-6 sensitivity in myeloid cells, indicating potential therapeutic targets.

Key Points

The V617F mutation in JAK2 significantly enhances sensitivity to IL-6 in myeloid cells, promoting chronic inflammation and disease progression.
Molecular dynamics simulations showed that JAK2VF forms more stable dimers than wild-type JAK2, leading to stronger STAT3 activation.
Increased gp130 receptor levels were observed in JAK2VF+ cells, enhancing their response to IL-6 stimulation compared to wild-type cells.
This mutation represents a critical target for therapies aimed at managing myeloproliferative neoplasms and associated inflammatory symptoms.

Cite This Study

Schurse et al. (2025) studied this question.

synapsesocial.com/papers/68ebffcfdef9fcb308ff230b https://doi.org/10.1101/2025.10.10.681590

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

View Full Paper

Ask AI

Bookmark